Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has received approval in Australia to commence a Phase I clinical study for its drug candidate APL-2301 (MET-102, formerly ASN-1733), which targets Acinetobacter baumannii infections. The study will evaluate the safety, tolerability, and pharmacokinetics of APL-2301 in healthy subjects and will also investigate the impact of drug-food interactions on the absorption and systemic exposure of the drug candidate.
Preclinical research indicates that APL-2301 exhibits potent activity against various clinically isolated strains of Acinetobacter baumannii, including carbapenem-resistant Acinetobacter baumannii (CRAB). The development of APL-2301 is anticipated to offer novel therapeutic options for patients battling Acinetobacter baumannii infections.- Fineline.com
